Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xenome and Amylin Pharmaceuticals have signed a joint research collaboration agreement, under which they will focus on the discovery and development of novel peptide therapeutics for a range of metabolic and musculoskeletal diseases.
Subscribe to our email newsletter
Under the collaboration, Amylin will apply its proprietary screening technologies to evaluate the therapeutic potential of the peptides from Xenome’s proprietary bioactive peptide library derived from natural sources. Amylin will have the right to select and exclusively license lead candidates resulting from a screening program in metabolic and musculoskeletal disease for further development and commercialization, in exchange for milestone payments and royalties payable to Xenome.
In addition to the joint research collaboration agreement, Amylin has made an equity investment in Xenome matched by investments from Queensland BioCapital Funds and Innovis Australia.
Michael Hanley, vice president of discovery research at Amylin, said: “This mutually beneficial collaboration combines Xenome’s proprietary peptide library with Amylin’s therapeutic expertise and creates valuable opportunities to discover and develop novel therapeutics.”